{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:13:25Z","timestamp":1789017205882,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BR-2955\/8"],"award-info":[{"award-number":["BR-2955\/8"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jtha.2023.07.027","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T01:27:27Z","timestamp":1691544447000},"page":"2718-2725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Five years of caplacizumab \u2013 lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"21","author":[{"given":"Linus Alexander","family":"V\u00f6lker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Thomas","family":"Brinkkoetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spero R.","family":"Cataland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Masias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.07.027_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.07.027_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1714146","article-title":"Ofatumumab for TTP in a Patient with anaphylaxis associated with rituximab","volume":"378","author":"Crowley","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.07.027_bib3","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A\u00a0phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.07.027_bib5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.07.027_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jtha.2023.07.027_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.07.027_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.07.027_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A\u00a0regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib10","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world evidence of caplacizumab use in the management of acute TTP","volume":"137","author":"Dutt","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib11","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs standard of care in immune thrombotic thrombocytopenic purpura","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.07.027_bib12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","article-title":"Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis","volume":"5","author":"Peyvandi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.07.027_bib13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","article-title":"Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura","volume":"21","author":"V\u00f6lker","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.07.027_bib14","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.07.027_bib15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib16","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(20)30406-3","article-title":"NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura","volume":"8","author":"Hughes","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.07.027_bib17","first-page":"43","article-title":"Cost-effectiveness analysis of caplacizumab in the new standard of care for immune thrombotic thrombocytopenic purpura in Italy","volume":"8","author":"Minno","year":"2021","journal-title":"Glob Reg Health Technol Assess"},{"key":"10.1016\/j.jtha.2023.07.027_bib18","first-page":"1178","article-title":"Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective","volume":"24","author":"Pollissard","year":"2021","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jtha.2023.07.027_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.07.027_bib53","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/trf.17111","article-title":"Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: a single-center with homogeneous treatment experience","volume":"62","author":"Jim\u00e9nez","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2023.07.027_bib54","first-page":"3418","article-title":"Post approval experience with caplacizumab for acquired thrombotic thrombocytopenic purpura at a single institution","volume":"10","author":"Logothetis","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2023.07.027_bib55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00277-022-05049-6","article-title":"Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura","volume":"102","author":"Meek","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtha.2023.07.027_bib56","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12185-022-03495-6","article-title":"The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2\/3 study","volume":"117","author":"Miyakawa","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2023.07.027_bib57","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2022.2157807","article-title":"Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience","volume":"34","author":"Tse","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.jtha.2023.07.027_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.103011","article-title":"Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI)","volume":"60","author":"Cid","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtha.2023.07.027_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103722","article-title":"Real-world data of the use and experience of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura: case series","volume":"62","author":"Albanell-Fern\u00e1ndez","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtha.2023.07.027_bib60","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1182\/blood-2022-158549","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura: real-world multicenter data on re-administration and plasma exchange free treatment","volume":"140","author":"Gavriilaki","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib61","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jval.2021.11.114","article-title":"POSB4 effectiveness of caplacizumab on reducing acute mortality in acquired thrombotic thrombocytopenic purpura: results from a French National registry (CNR-MAT)","volume":"25","author":"Vataire","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jtha.2023.07.027_bib62","author":"Agosti"},{"key":"10.1016\/j.jtha.2023.07.027_bib37","first-page":"2206","article-title":"Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era","volume":"141","author":"Prasannan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib20","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.07.027_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106431","article-title":"Cerebral infarction due to severe ADAMTS-13 deficiency with normal hematological parameters: a cause of cryptogenic stroke","volume":"31","author":"Matthews","year":"2022","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jtha.2023.07.027_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-017-2264-7","volume":"106","author":"Matsumoto","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2023.07.027_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2023.07.027_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.24665","article-title":"Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre","volume":"92","author":"Grall","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2023.07.027_bib25","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/1744-9987.12713","article-title":"Predictive value of schistocytes in recurrence of acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency at discontinuation of daily therapeutic plasma exchange","volume":"22","author":"Peedin","year":"2018","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jtha.2023.07.027_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0039-1679907","article-title":"Clinical and laboratory features of patients with acquired thrombotic thrombocytopenic purpura: fourteen years of the Milan TTP registry","volume":"119","author":"Mancini","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.07.027_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/hematology.2022000412","article-title":"Evidence-based minireview: should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?","author":"Goshua","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2023.07.027_bib28","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/ajh.25002","article-title":"No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry","volume":"93","author":"Masias","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2023.07.027_bib29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2021-146282","article-title":"Mortality in acute immune-mediated thrombotic thrombocytopenic purpura (iTTP) is unpredictable: poor statistical performance of mortality prediction models","volume":"138","author":"Abou-Ismail","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura","volume":"381","author":"Chander","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.07.027_bib32","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/trf.15823","article-title":"Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma","volume":"60","author":"Irani","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2023.07.027_bib33","author":"Kn\u00f6bl"},{"key":"10.1016\/j.jtha.2023.07.027_bib34","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1002\/ajh.25715","article-title":"Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab","volume":"95","author":"Sukumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2023.07.027_bib35","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"V\u00f6lker","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.07.027_bib36","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.07.027_bib38","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jth.15637","article-title":"Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura","volume":"20","author":"K\u00fchne","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.07.027_bib42","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc N Y Pathol Soc"},{"key":"10.1016\/j.jtha.2023.07.027_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archinte.1925.00120130092009","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease","volume":"36","author":"Moschcowitz","year":"1925","journal-title":"Arch Intern Med (Chic)"},{"key":"10.1016\/j.jtha.2023.07.027_bib44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.07.027_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.07.027_bib46","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"7","author":"Djulbegovic","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.07.027_bib47","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2022-167054","article-title":"Silent cerebral infarction during immune TTP remission - prevalence, predictors and impact on cognition","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib48","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is\u00a0associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2021.100062","article-title":"Updates on thrombotic thrombocytopenic purpura: recent developments in pathogenesis, treatment and survivorship","volume":"5","author":"Sukumar","year":"2021","journal-title":"Thromb Update"},{"key":"10.1016\/j.jtha.2023.07.027_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-138551","article-title":"Cardiovascular disease Is a leading cause of death in thrombotic thrombocytopenic purpura (TTP) survivors","volume":"136","author":"Sukumar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.07.027_bib51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/j.ajkd.2014.03.019","article-title":"Increased urinary albumin excretion following recovery from thrombotic thrombocytopenic purpura due to acquired ADAMTS13 deficiency","volume":"64","author":"Little","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jtha.2023.07.027_bib52","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/asheducation-2018.1.548","article-title":"TTP: long-term outcomes following recovery","author":"George","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623005913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623005913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:41:01Z","timestamp":1742283661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623005913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1538783623005913"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.07.027","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five years of caplacizumab \u2013 lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}